LON:STX Shield Therapeutics (STX) Share Forecast, Price & News GBX 11.25 0.00 (0.00%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range 11.03▼ 11.7050-Day Range 6.40▼ 11.5552-Week Range 5.80▼ 12.50Volume1.46 million shsAverage Volume2.45 million shsMarket Capitalization£80.22 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsInsider TradesHeadlinesOptions ChainProfileAnalyst RatingsChartCompetitorsInsider TradesHeadlinesOptions Chain About Shield Therapeutics (LON:STX) StockShield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.Read More STX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart STX Stock News HeadlinesSeptember 5, 2023 | finance.yahoo.comPrivate companies who hold 41% of Shield Therapeutics plc (LON:STX) gained 17%, institutions profited as wellJuly 29, 2023 | proactiveinvestors.comShield Therapeutics : First signs of hoped-for Accrufer Rx inflectionSeptember 24, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...July 25, 2023 | finanznachrichten.deHardman & Co Research on Shield Therapeutics (STX): Accrufer Rx momentum gatheringJuly 25, 2023 | finance.yahoo.comShield Therapeutics "really starting to fire on all cylinders"July 20, 2023 | marketwatch.comShield Therapeutics Shares Rise as US Prescriptions for Accrufer SoarJuly 20, 2023 | msn.comShield Therapeutics makes waves in US as iron deficiency prescriptions ramp upJuly 20, 2023 | proactiveinvestors.comShield Therapeutics reports 173% Accrufer prescription growthSeptember 24, 2023 | Legacy Research (Ad)Elon Did It Again: This Could be Bigger than TeslaLove him or hate him, it’s hard to deny Elon Musk is a genius. After revolutionizing online payment processing (PayPal), space exploration (SpaceX), and the auto industry (Tesla)... He’s getting ready to do it again with his new AI venture.July 11, 2023 | msn.comSave $30 on the Nvidia Shield Android TV for Amazon Prime DayJuly 7, 2023 | msn.comNeutral Swiss join Europe's Sky Shield defenceJuly 4, 2023 | barrons.comSwiss Want In On Germany's Sky Shield PlanMay 17, 2023 | uk.movies.yahoo.comHardman & Co Research on Shield Therapeutics (STX): Reassuring 1Q’23 Accrufer prescriptionsMay 4, 2023 | proactiveinvestors.comShield Therapeutics directors urge rejection of mandatory offerMay 2, 2023 | proactiveinvestors.comShield Therapeutics well positioned with "great partnership" - Proactive Research AnalystApril 27, 2023 | proactiveinvestors.comShield Therapeutics ready to go full throttle in the USApril 5, 2023 | proactiveinvestors.comShield Therapeutics appoints chief commercial officer as group readies for US sales offensiveMarch 27, 2023 | finance.yahoo.comLoss-Making Shield Therapeutics plc (LON:STX) Expected To Breakeven In The Medium-TermFebruary 13, 2023 | finance.yahoo.comShield Therapeutics "ended 2022 in a very very productive state"February 13, 2023 | finance.yahoo.comProactive research analyst says Shield Therapeutics "in fast growth mode"February 9, 2023 | benzinga.comPrivacy Shield: The Six Things You Need to Know That Might Affect Your CompanyFebruary 9, 2023 | proactiveinvestors.comShield Therapeutics primed for a strong year as it confirms plans to become self-sufficientFebruary 9, 2023 | proactiveinvestors.comShield Therapeutics shares jump 13%; broker sets punchy price targetJanuary 23, 2023 | markets.businessinsider.comHardman & Co Q&A on Shield Therapeutics (STX): Positioned for profitability with Viatris deal and its additional capitalJanuary 13, 2023 | uk.finance.yahoo.comHardman & Co Research: Shield Therapeutics (STX) - Positioned for growth and profitabilityDecember 14, 2022 | proactiveinvestors.comProactive research analyst on Shield TherapeuticsDecember 14, 2022 | proactiveinvestors.comShield Therapeutics completes fundraiseSee More Headlines Receive STX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Shield Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON Industry Drug Manufacturers—Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolLON:STX CUSIPN/A CIKN/A Webwww.shieldtherapeutics.com Phone+44-191-5118500FaxN/AEmployees27Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.16) Trailing P/E RatioN/A Forward P/E Ratio72.62 P/E GrowthN/ANet Income£-40,440,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-175.39% Return on Assets-48.33% Debt Debt-to-Equity Ratio103.76 Current Ratio0.95 Quick Ratio2.16 Sales & Book Value Annual Sales£4.47 million Price / Sales17.95 Cash FlowGBX 1.77 per share Price / Cash Flow6.36 Book ValueGBX 2 per share Price / Book5.63Miscellaneous Outstanding Shares713,040,000Free FloatN/AMarket Cap£80.22 million OptionableOptionable Beta1.17 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Gregory P. Madison (Age 55)CEO & Exec. Director Comp: $678kDr. Christian Schweiger M.D. (Age 56)Ph.D., Co-Founder & Non Exec. Director Comp: $45kMr. Hans-Peter RudolfChief Financial OfficerMs. Lucy Kate Huntington-BaileyGen. Counsel & Company Sec.Ms. Suzanne WoodGroup HR DirectorMs. Carol AkinolaHead of Pharmacovigilance & Medical InformationMr. Andrew Hurley (Age 54)Chief Commercial Officer Kate ArmanettiSr. Director of People & CultureMore ExecutivesKey CompetitorsECO Animal Health GroupLON:EAHCeladon PharmaceuticalsLON:CELAnimalcare GroupLON:ANCRVenture Life GroupLON:VLGBeximco PharmaceuticalsLON:BXPView All CompetitorsInsidersGreg MadisonSold 466,395 sharesTotal: £3.26 M ($7.00/share)View All Insider Transactions STX Stock - Frequently Asked Questions Should I buy or sell Shield Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Shield Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" STX shares. View STX analyst ratings or view top-rated stocks. How have STX shares performed in 2023? Shield Therapeutics' stock was trading at GBX 7.05 at the beginning of 2023. Since then, STX stock has increased by 59.6% and is now trading at GBX 11.25. View the best growth stocks for 2023 here. What other stocks do shareholders of Shield Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Shield Therapeutics investors own include AcelRx Pharmaceuticals (ACRX), Rockwell Medical (RMTI), Cara Therapeutics (CARA), Caladrius Biosciences (CLBS), Cellectis (CLLS), Geron (GERN), Concepta PLC (CPT.L) (CPT), Fresnillo (FRES), OptiBiotix Health (OPTI) and SkinBioTherapeutics (SBTX). What is Shield Therapeutics' stock symbol? Shield Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "STX." How do I buy shares of Shield Therapeutics? Shares of STX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is Shield Therapeutics' stock price today? One share of STX stock can currently be purchased for approximately GBX 11.25. How much money does Shield Therapeutics make? Shield Therapeutics (LON:STX) has a market capitalization of £80.22 million and generates £4.47 million in revenue each year. The company earns £-40,440,000.00 in net income (profit) each year or GBX (0.16) on an earnings per share basis. How can I contact Shield Therapeutics? Shield Therapeutics' mailing address is 3rd Fl Baltic Business Quarters, Abbott's Hill, GATESHEAD, NE8 3D, United Kingdom. The official website for the company is www.shieldtherapeutics.com. The company can be reached via phone at +44-191-5118500. This page (LON:STX) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shield Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.